The association between methylenetetrahydrofolate reductase C677T polymorphism and cervical cancer

authors:

avatar Mogge Hajiesmaeil , avatar Farzaneh Tafvizi , * , avatar Soheila Sarmadi

Koomesh: Vol.17, issue 3; 651-659
published online: May 28, 2016
article type: Research Article
received: September 08, 2015
accepted: December 03, 2015

how to cite: Hajiesmaeil M, Tafvizi F, Sarmadi S. The association between methylenetetrahydrofolate reductase C677T polymorphism and cervical cancer. koomesh. 2016;17(3):e151213. 

Abstract

Introduction: Cervical cancer is one of the common cancers in women. Several factors can lead to cervical cancer among which, infection with human papilloma virus (HPV), abnormal epigenetic changes such as methylation of gene promoter, methylene tetrahydrofolatereductase (MTHFR) polymorphisms such as MTHFR C677T polymorphism are notable. MTHFR is an enzyme that plays a role in regulating the metabolism of folate and methionine. This study was aimed to illustrate the relationship between MTHFR gene C677T polymorphism and the risk of cervical cancer. Materials and Methods: This study examined 100 cervical cancerous tissues in compare to 100 cytology samples of normal healthy women without HPV infection. The age status of both groups was between (20-45) years old. PCR-RFLP was used for MTHFR polymorphism detection. Results: The results showed a significant correlation between the CT and TT genotypes and reduced risk of cervical cancer. Hardy-Weinberg equilibrium calculation showed that there was not any significant differences between observed and predicted genotypes hence, the population of patients and the healthy participants for both loci were in balance. Conclusion: There was an increased risk of cervical cancer in individuals with genotype CC. It is more likely that allele C to be a high-risk allele, increasing the risk of cancer. Allele T, probably acts as a protective allele, which reduces the risk of the disease (OR: 0.5, % 95 CI: 0.28 - 0.89, P = 0.028).

References

  • 1.

    Mortazavi S, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev 2002; 3: 69-72.

  • 2.

    Luhn P1, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol 2013; 128: 265-270.

  • 3.

    Tanton C, Soldan K, Beddows S, Mercer CH, Waller J, Field N, et al. High-Risk human papillomavirus (HPV) infection and cervical cancer prevention in britain: evidence of differential uptake of interventions from a probability survey. Cancer Epidemiol Biomarkers Prev 2015; 24: 842-853.

  • 4.

    Tran P, Leclerc D, Chan M, Pai A, Hiou-Tim F, Wu Q, et al. Multiple transcription start sites and alternative splicing in the methylenetetrahydrofolate reductase gene result in two enzyme isoforms. Mamm Genome 2002; 13: 483-492.

  • 5.

    Goyette, P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am J Hum Genet 1996; 59: 1268-1275.

  • 6.

    Tonetti C, Burtscher A, Bories D, Tulliez M, Zittoun J. Methylenetetrahydrofolate reductase deficiency in four siblings: clinical, biochemical, and molecular study of the family. Am J Med Genet 2000; 91: 363-367.

  • 7.

    Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increase in plasma S-asenosylhomocystein and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275: 29318-29323.

  • 8.

    Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.

  • 9.

    Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahy drofolate reductase (MTHER). Thromb Haemost 1997; 78: 523-526.

  • 10.

    Kohaar I, Kumar J, Thakur N, Hussain S, Niyaz MK, Das BC, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population. Biomarkers 2010; 15: 61-68.

  • 11.

    Badiga S, Johanning GL, Macaluso M, Azuero A, Chambers MM, Siddiqui NR, et al. A lower degree of PBMC L1 methylation in women with lower folate status may explain the MTHFR C677T polymorphism associated higher risk of CIN in the US post folic acid fortification era. PLoS One 2014; 9: e110093.

  • 12.

    Tomita LY, D'Almeida V, Villa LL, Franco EL, Cardoso MA. Polymorphisms in genes involved in folate metabolism modify the association of dietary and circulating folateand vitamin B-6 with cervical neoplasia. J Nutr 2013; 143: 2007-2014.

  • 13.

    Sibani S, Leclerc D, Weisberg IS, O'Ferrall E, Watkins D, Artigas C, et al. Characterization of mutations in severe methylenetetrahydrofolate reductase deficiency reveals an FAD responsive mutation. Hum Mutat 2003; 21: 509-520.

  • 14.

    Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF. Evaluation of extraction method from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 2001; 54: 401-403.

  • 15.

    Abbate R, Sardi I, Pepe G, Marcucci R, Brunelli T, Prisco D, et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 727-730.

  • 16.

    Summary Report Update. 3rd ed 2010. Human Papillomavirus and Related Cancers. WHO/ICO HPV information center.

  • 17.

    Mwaka AD, Orach CG, Were EM, Lyratzopoulos G, Wabinga H, Roland M. Awareness of cervical cancer risk factors and symptoms: cross-sectional community survey in post-conflict northern Uganda. Health Expect 2015; 23.

  • 18.

    Li J, Mei J, Wang X, Hu L, Lin Y, Yang P. Human papillomavirus type-specific prevalence in women with cervical intraepithelial neoplasm in Western China. J Clin Microbiol 2012; 50: 1079-1081.

  • 19.

    Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-1059.

  • 20.

    Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 1972; 46: 905-912.

  • 21.

    Tong SY, Kim MK, Lee JK, Lee JM, Choi SW, Friso S, et al. Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks ofcervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitaminB12. Cancer Causes Control 2011; 22: 63-72.

  • 22.

    Nandan NK, Wajid S, Biswas S, Juneja SS, Rizvi M, Prakash R, et al. Allelic variations in 5, 10-methylenetetrahydrofolate reductase gene and susceptibility tocervical cancer in Indian women. Drug Metab Lett 2008; 2: 18-22.

  • 23.

    Goodman MT, McDuffie K, Hernandez B, Wilkens LR, Bertram CC, Killeen J, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk ofcervical dysplasia. Cancer Epidemiol Biomarkers Prev 2001; 10: 1275-1280.

  • 24.

    Sull JW, Jee SH, Yi S, Lee JE, Park JS, Kim S, et al. The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol 2004; 95: 557-563.

  • 25.

    Lambropoulos AF, Agorastos T, Foka ZJ, Chrisafi S, Constantinidis TC, Bontis J, et al. Methylene tetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 2003; 191: 187-191.

  • 26.

    Prasad VV, Wilkhoo H. Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie 2011; 34: 422-426.

  • 27.

    Mostowska A, Myka M, Lianeri M, Roszak A, Jagodziski PP. Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem 2011; 44: 596-600.

  • 28.

    Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005; 96: 173-180.

  • 29.

    Kohaar I, Kumar J, Thakur N, Hussain S, Niyaz MK, Das BC, et al. Homocysteine levels are associated with cervical cancer independent of methylenetetrahydrofolate reductasegene (MTHFR) polymorphisms in Indian population. Biomarkers 2010; 15: 61-68.

  • 30.

    Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre) neoplastic cervicaldisease. Hum Genet 2005; 116: 247-254.

  • 31.

    Piyathilake CJ, Macaluso M, Johanning GL, Whiteside M, Heimburger DC, Giuliano A. Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervicalintraepithelial neoplasia. Anticancer Res 2000; 20: 1751-1757.

  • 32.

    Shekari M, Sobti RC, Kordi Tamandani DM, Suri V. Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet 2008; 278: 517-524.

  • 33.

    Piyathilake CJ, Azrad M, Macaluso M, Johanning GL, Cornwell PE, Partridge EE, et al. Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition 2007; 23: 229-235.

  • 34.

    Agodi A, Barchitta M, Cipresso R, Marzagalli R, La Rosa N, Caruso M, et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily. Int J Gynecol Cancer 2010; 20: 141-146.

  • 35.

    Mei Q, Zhou D, Gao J, Shen S, Wu J, Guo L, et al. The association between MTHFR 677C>T polymorphism and cervical cancer: evidence from a meta-analysis. BMC Cancer 2012; 12: 467.